Rani Therapeutics Holdings (RANI) EBT Margin (2020 - 2026)

Rani Therapeutics Holdings (RANI) posted EBT Margin of 493.03% for Q2 2026, down 5.07% on a QoQ basis from 469.26% in Q1 2026.

Analysis

Rani Therapeutics Holdings (RANI) EBT Margin (2020 - 2026) Analysis & Trends

Rani Therapeutics Holdings has reported EBT Margin for 5 years, with the latest figure at 493.03% in Q2 2026.

On a quarterly basis, EBT Margin changed N/A year-over-year to 493.03% in Q2 2026; TTM through Jun 2026 was 673.53%, a 369364.0% increase from a year earlier, with the FY2025 full-year figure at 2472.38%, up 303190.0% from the prior year.
EBT Margin was 493.03% for Q2 2026 at Rani Therapeutics Holdings, down from 469.26% in the prior quarter.
The five-year high for EBT Margin was 469.26% in Q1 2026, with the low at 7405.81% in Q1 2025.
Average EBT Margin over 3 years is 2095.83%, with a median of 581.66% recorded in 2025.
The sharpest annual moves came in 2025 and 2026: EBT Margin jumped 94772 bps in 2025, then soared 693655 bps in 2026.
Over 3 years, EBT Margin stood at 1529.38% in 2024, then jumped by 62 bps to 581.66% in 2025, then gained by 15 bps to 493.03% in 2026.
The last three EBT Margin figures came in at 493.03% (Q2 2026), 469.26% (Q1 2026), and 581.66% (Q4 2025), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Amgen	203.97 Bn	189.99 Bn	7.24 Bn	27.53%
2	Gilead Sciences	178.74 Bn	175.56 Bn	6.22 Bn	-131.41%
3	Vertex Pharmaceuticals	130.73 Bn	122.88 Bn	2.84 Bn	41.75%
4	Regeneron Pharmaceuticals	80.42 Bn	72.42 Bn	3.93 Bn	35.61%
5	Argenx Se	60.40 Bn	55.21 Bn	1.37 Bn	35.78%
6	Moderna	57.65 Bn	52.52 Bn	52.00 Mn	-528.97%
7	Alnylam Pharmaceuticals	33.37 Bn	30.07 Bn	992.69 Mn	13.77%
8	Biogen	32.15 Bn	30.86 Bn	1.96 Bn	4.84%
9	Roivant Sciences	29.58 Bn	29.58 Bn	1.16 Mn	-20,427.46%
10	Rani Therapeutics Holdings	157.97 Mn	157.97 Mn	-	-493.03%

Historic Data

Download Data